Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.47 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.47 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364727 | 0.88 | ADORA2A (0.49) | ADORA2AADORA1CYP3A4CYP2D6HTR4 | |
| SCHEMBL1367559 | 0.88 | DGAT1 (0.51) | ADORA2AADORA1CYP3A4CYP2D6HTR4 | |
| SCHEMBL12141988 | 0.88 | ATR (0.55) | ALDH1A1GABRA5ACVR1BMPR1BBMPR1A | |
| SCHEMBL14094614 | 0.87 | CKS1B (0.47) | PTPN11ALDH1A1ACVR1BMPR1BBMPR1A | |
| SCHEMBL1366693 | 0.87 | PARP1 (0.49) | ADORA2AADORA1PTPN11HTR4ALDH1A1 | |
| SCHEMBL14094611 | 0.85 | ALDH1A1 (0.49) | PTPN11ALDH1A1ACVR1BMPR1BBMPR1A | |
| SCHEMBL1366327 | 0.83 | GABRA5 (0.57) | ADORA2AADORA1CYP3A4CYP2D6HTR4 | |
| SCHEMBL1365048 | 0.79 | DRD4 (0.60) | CYP2D6ALDH1A1PARP1MAPTRAB9A | |
| SCHEMBL1364526 | 0.78 | SLC6A12 (0.56) | CYP3A4CYP2D6DRD4 | |
| SCHEMBL1364923 | 0.76 | DGAT1 (0.53) | ALDH1A1GABRA5DYRK1AATRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2132196-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2008104869-A1 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | ADORA2A 2744/4885ADORA1 2120/4885PTPN11 3825/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | ADORA2A 2744/4885ADORA1 2120/4885PTPN11 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.